Cardinal Health (NYSE:CAH) Upgraded by Zacks Research to Strong-Buy Rating

Cardinal Health (NYSE:CAH) was upgraded by equities researchers at Zacks Research from a “hold” rating to a “strong-buy” rating in a report issued on Thursday,Zacks.com reports.

Other equities analysts have also recently issued research reports about the company. Morgan Stanley set a $255.00 price target on Cardinal Health in a report on Friday, February 6th. JPMorgan Chase & Co. increased their target price on Cardinal Health from $209.00 to $243.00 and gave the company a “neutral” rating in a research report on Tuesday. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Cardinal Health from $195.00 to $208.00 and gave the stock a “hold” rating in a research report on Tuesday, November 18th. Citigroup upgraded shares of Cardinal Health from a “neutral” rating to a “buy” rating and increased their price objective for the company from $190.00 to $244.00 in a research report on Friday, January 9th. Finally, Wells Fargo & Company lifted their price objective on shares of Cardinal Health from $237.00 to $256.00 and gave the stock an “overweight” rating in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $245.19.

Cardinal Health Price Performance

Shares of CAH opened at $220.72 on Thursday. The firm has a market cap of $51.94 billion, a P/E ratio of 31.76, a price-to-earnings-growth ratio of 1.39 and a beta of 0.64. Cardinal Health has a 1 year low of $120.72 and a 1 year high of $230.81. The company has a 50 day simple moving average of $208.84 and a two-hundred day simple moving average of $182.20.

Cardinal Health (NYSE:CAH) last released its earnings results on Thursday, February 5th. The company reported $2.63 EPS for the quarter, topping the consensus estimate of $2.31 by $0.32. The firm had revenue of $65.63 billion for the quarter, compared to the consensus estimate of $64.88 billion. Cardinal Health had a net margin of 0.68% and a negative return on equity of 92.50%. The company’s quarterly revenue was up 18.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.93 earnings per share. On average, sell-side analysts anticipate that Cardinal Health will post 7.95 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Aventura Private Wealth LLC bought a new stake in shares of Cardinal Health during the 4th quarter worth approximately $25,000. Bank of Jackson Hole Trust bought a new position in Cardinal Health in the 4th quarter valued at $27,000. Palladiem LLC purchased a new stake in Cardinal Health in the fourth quarter worth $28,000. SJS Investment Consulting Inc. lifted its position in shares of Cardinal Health by 1,363.6% during the third quarter. SJS Investment Consulting Inc. now owns 161 shares of the company’s stock worth $25,000 after purchasing an additional 150 shares during the last quarter. Finally, Elyxium Wealth LLC bought a new stake in shares of Cardinal Health during the fourth quarter worth $34,000. Hedge funds and other institutional investors own 87.17% of the company’s stock.

Key Cardinal Health News

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Recent quarterly results and underlying strength — Cardinal reported a Q4 EPS beat and revenue above expectations, with revenue up ~19% year-over-year, which analysts cite as supporting the stock’s upside. Cardinal Health’s (NYSE:CAH) Solid Earnings Are Supported By Other Strong Factors
• Positive Sentiment: Dividend confirmed — the Board approved a quarterly dividend of $0.5107 per share (payable Apr 15; record Apr 1). The cash return reinforces income appeal and signals confidence in cash flow. Cardinal Health Board of Directors Approves Quarterly Dividend
• Positive Sentiment: Analyst lift — JPMorgan raised its price target to $243, providing a tangible upside anchor for investors and helping sentiment. JPMorgan Chase Increases Cardinal Health Price Target
• Positive Sentiment: Zacks momentum & valuation coverage — CAH was added to Zacks’ Rank #1 momentum list and several Zacks pieces highlight undervaluation and a favorable long-term value case, which can attract momentum and value investors. Best Momentum Stock to Buy for February 13th Are Investors Undervaluing Cardinal Health?
• Neutral Sentiment: Kalkine notes logistics/reliability improvements on the NYSE composite — operational reliability updates are constructive but are incremental near-term drivers. Cardinal Health Boosts Logistics Reliability
• Neutral Sentiment: Analyst Q&A from the earnings call — the transcript highlights management’s priorities and risk items; useful for longer-term fundamental assessment but not an immediate catalyst. The 5 Most Interesting Analyst Questions From Cardinal Health’s Q4 Earnings Call

Cardinal Health Company Profile

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.